Gelomics, a pioneering Australian biotech firm redefining the future of drug development with its cutting-edge 3D tissue culture technologies, is delighted to announce the appointment of Distinguished Professor Gail Risbridger AM to its Scientific Advisory Board. 

Professor Risbridger joins a team of internationally recognized scientific leaders, bringing a wealth of expertise in translational research and clinical trial innovation to Gelomics’ mission of advancing ethical, human-relevant drug development platforms. 

“We are honored to welcome Gail to our Scientific Advisory Board. Her legacy of translational research and policy-shaping discoveries in men’s health and oncology will play a pivotal role in guiding our scientific strategy as we continue to develop next-generation tissue culture systems to accelerate safer, more predictive drug discovery.” 

— Dr Christoph Meinert, CEO of Gelomics 

About Distinguished Professor Gail Risbridger AM 

Professor Gail Risbridger is a globally renowned leader in men’s health, urology, and translational oncology. As a Distinguished Professor at Monash University, she leads internationally recognized, multidisciplinary research programs aimed at accelerating drug development and clinical translation. 

Her pioneering work has driven critical policy and practice changes in Urology, Oncology, and Pathology—both nationally and globally—including shaping the Australian National Men’s Health Policy. Her exceptional contributions have been recognized by a host of honors, including: 

• Fulbright Senior Scholar Award (2001) 

• Four NH&MRC Research Fellowships (1996–2021) 

• Endocrine Society of Australia Lifetime Achievement and Senior Plenary Awards (2008 & 2012) 

• Fellow of the Society of Reproductive Biology (2015) 

• Fellow of the Australian Academy of Health and Medical Science (2019) 

• Member of the Order of Australia (AM) in 2023 Australia Day Honours 

With her appointment, Gelomics continues to strengthen its scientific foundation to deliver world-class, non-animal solutions for drug development and personalized medicine. 

About Gelomics 

Gelomics is an Australian biotechnology company revolutionising drug development through non-animal, 3D tissue culture technologies. Our LunaGel™ platform enables scientists to grow complex human tissues in vitro, providing more predictive and ethical solutions for drug efficacy and safety testing. By uniting scientific excellence with innovative engineering, Gelomics is reshaping the future of clinical research and regenerative medicine. 

Learn more about Gelomics’ innovative products and access our product catalogue: www.gelomics.com